These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 39241297)

  • 1. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
    Marks JA; Gandhi N; Halmos B; Marmarelis ME; Yeon Kim S; Bazhenova L; Ramalingam SS; Xiu J; Walker P; Oberley MJ; Ma PC; Liu SV
    Lung Cancer; 2024 Oct; 196():107935. PubMed ID: 39241297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of
    Kim SY; Yin J; Bohlman S; Walker P; Dacic S; Kim C; Khan H; Liu SV; Ma PC; Nagasaka M; Reckamp KL; Abraham J; Uprety D; Wang F; Xiu J; Zhang J; Cheng H; Halmos B
    JTO Clin Res Rep; 2022 Sep; 3(9):100381. PubMed ID: 36082279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
    Minne RL; Luo NY; Traynor AM; Huang M; DeTullio L; Godden J; Stoppler M; Kimple RJ; Baschnagel AM
    Clin Lung Cancer; 2024 Sep; 25(6):567-576.e1. PubMed ID: 38852006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
    Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and clinical characteristics of
    Cheng T; Gu Z; Song D; Liu S; Tong X; Wu X; Lin Z; Hong W
    J Cancer; 2021; 12(3):644-651. PubMed ID: 33403024
    [No Abstract]   [Full Text] [Related]  

  • 8. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
    Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
    Front Oncol; 2022; 12():786124. PubMed ID: 35280795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of
    Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
    JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring
    Yu Y; Ren Y; Fang J; Cao L; Liang Z; Guo Q; Han S; Ji Z; Wang Y; Sun Y; Chen Y; Li X; Xu H; Zhou J; Jiang L; Cheng Y; Han Z; Shi J; Chen G; Ma R; Fan Y; Sun S; Jiao L; Jia X; Wang L; Lu P; Xu Q; Luo X; Su W; Lu S
    Ther Adv Med Oncol; 2022; 14():17588359221133546. PubMed ID: 36339926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
    Lefebvre AM; Adam J; Nicolazzi C; Larois C; Attenot F; Falda-Buscaiot F; Dib C; Masson N; Ternès N; Bauchet AL; Demers B; Chadjaa M; Sidhu S; Combeau C; Soria JC; Scoazec JY; Naimi S; Angevin E; Chiron M; Henry C
    Lung Cancer; 2023 Oct; 184():107356. PubMed ID: 37660479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance.
    Chen S; Hu T; Zhao J; Zhu Q; Wang J; Huang Z; Xiang C; Zhao R; Zhu C; Lu S; Han Y
    NPJ Precis Oncol; 2024 Jul; 8(1):159. PubMed ID: 39060379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
    Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
    Front Oncol; 2021; 11():649766. PubMed ID: 34249687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
    Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with
    Digumarthy SR; Mendoza DP; Zhang EW; Lennerz JK; Heist RS
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31861060
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
    Baldacci S; Figeac M; Antoine M; Descarpentries C; Kherrouche Z; Jamme P; Copin MC; Tulasne D; Nanni I; Beau-Faller M; Melaabi S; Levallet G; Quoix E; Moro-Sibilot D; Friard S; Missy P; Barlesi F; Cadranel J; Cortot AB
    J Thorac Oncol; 2020 Jan; 15(1):120-124. PubMed ID: 31605799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and immune phenotypes associated with
    Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
    J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.